Cargando…

Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)

To compare the efficacy of methotrexate and apremilast in psoriatic arthritis (PsA). This Single blinded (physician), parallel group, randomized controlled trial was conducted at a single centre between October 2019 and December 2020. Adult PsA patients (age > 18 years), fulfilling CASPAR criteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samanta, Joydeep, Naidu, GSRSNK, Chattopadhyay, Arghya, Basnet, Amal, Narang, Tarun, Dhir, Varun, Dogra, Sunil, Jain, Sanjay, Sharma, Aman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037372/ https://www.ncbi.nlm.nih.gov/pubmed/36961603 http://dx.doi.org/10.1007/s00296-023-05315-4

Ejemplares similares

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study
por: Samanta, Joydeep, et al.
Publicado: (2022)

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
por: Arias de la Rosa, Ivan, et al.
Publicado: (2022)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial
por: Bhargava, Mudit, et al.
Publicado: (2023)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Intravenous Immunoglobulin for the Rescue in Refractory Cutaneous Lupus
por: Singh, Harpreet, et al.
Publicado: (2020)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Crystal, but not Clear
por: Samanta, Joydeep, et al.
Publicado: (2022)

A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
por: Srivastava, Divyanshu, et al.
Publicado: (2023)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Carpet Tack Sign
por: Samanta, Joydeep, et al.
Publicado: (2021)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Dermoscopy as a Tool to Differentiate Reactive Arthritis from Psoriatic Arthritis
por: Razmi, Muhammed T., et al.
Publicado: (2022)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
por: Husni, M Elaine, et al.
Publicado: (2022)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
por: Ferguson, Lyn D, et al.
Publicado: (2021)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Low Serum Levels of Myeloid Progenitor Inhibitory Factor-1 Predict Good Response to Methotrexate in Rheumatoid Arthritis
por: Dhir, Varun, et al.
Publicado: (2013)

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019)

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
por: Nisar, Muhammad K.
Publicado: (2019)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
por: Becciolini, Andrea, et al.
Publicado: (2023)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
por: de Vlam, Kurt, et al.
Publicado: (2022)

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Pina Vegas, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pl4tqvih6kjvgs6bocmhtc1451